Of note, the ORR observed in patients with FL treated with urelumab plus rituximab in this study was similar to that observed with another anti‐CD137 agonist, utomilumab, evaluated in combination with rituximab (four doses) in patients with rituximab‐refractory FL (ORR, 33% [n = 24, dose escalation] and 44% [n = 9, cohort expansion]).28 Variable trends of PFS and OS observed in CA186‐011 and CA186‐017 have also been reported in studies evaluating recommended regimens for R/R FL and DLBCL.3 The gene discussed is TNFRSF9; the disease is diffuse large B-cell lymphoma.